IC Targets develops manganese-based contrast agents to address unmet medical needs.
Our new, game changing Magnetic Resonance Imaging (MRI) contrast agent and procedure for cardiac imaging will lead to validation of new treatments. Improvements in therapy require better characterization of myocardial function, where cardiac MRI has become increasingly important.
IC Targets pursues the application of its manganese-based contrast agent, mangafodipir trisodium, in additional indications, such as detection of focal lesions of the liver and the pancreas. Mangafodipir trisodium is a gadolinium free MRI agent, which helps to improve clarity of radiology images and provides physicians with information for diagnosis.
IC Targets is privately owned by Norwegian private and institutional investors.
The company is based in Oslo, Norway.